Who
Julie Smith
Director
Company insider
Files Form 4 as: Director, Stoke Therapeutics; Director, Exelixis; Director, Audentes Therapeutics; President and CEO, Raptor Pharmaceutical.
In numbers
- Trades disclosed
- 72
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $12.8M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 10 Sep 2012
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,786 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,786 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $855K44,087 at $19.39 | filing |
| 18 Feb 2026filed 19 Feb 2026 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —44,087 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,030 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $2.0M44,087 at $44.50 | filing |
| 18 Feb 2026filed 19 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $434K20,030 at $21.69 | filing |
| 18 Feb 2026filed 19 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $887K20,030 at $44.30 | filing |
| 18 Feb 2026filed 19 Feb 2026 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —44,087 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $855K44,087 at $19.39 | filing |
| 18 Feb 2026filed 19 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $2.0M44,087 at $44.50 | filing |
| 18 Feb 2026filed 19 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $434K20,030 at $21.69 | filing |
| 18 Feb 2026filed 19 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $887K20,030 at $44.30 | filing |
| 18 Feb 2026filed 19 Feb 2026 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,030 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $772K42,422 at $18.19 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.8M42,422 at $43.33 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —42,422 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —42,422 at $0.00 | filing |
News
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockEXEL · tickerreport.com · 21 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026
0 headlines in the last 90 days name Julie Smith; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.